Details of the Drug
General Information of Drug (ID: DMIAUB1)
| Drug Name |
Biphenyl-3-ylboronic acid
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
3-Biphenylboronic acid; 5122-95-2; Biphenyl-3-boronic acid; [1,1'-Biphenyl]-3-ylboronic acid; biphenyl-3-ylboronic acid; (3-phenylphenyl)boronic Acid; 3-biphenyl boronic acid; (3-phenylphenyl)boranediol; 3-PHENYLBENZENEBORONIC ACID; (1,1'-biphenyl-3-yl)boronic acid; [1,1'-Diphenyl]-3-ylboronic acid; MFCD01318102; Boronic acid, [1,1'-biphenyl]-3-yl-; AK-35405; Biphenyl-3-boronicacid; PubChem6404; Phenylboronic Acid, 5; Biphenyl-3-bronic acid; 3-biphenyl-boronic acid; ACMC-1AKSL; AC1MC0UE; Biphenyl-3-ylbronic acid
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 198.03 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


